Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GRI

- PMLiVE

Sanofi launches ‘Highs & Lows’ diabetes awareness campaign

Highlights impact of emotional and psychological factors on effective self-management

Sanofi reception

FDA clears rival diabetes combos from Sanofi and Novo Nordisk

Xultophy set to launch in first half of 2017 while Soliqua is intended for January roll-out

- PMLiVE

Gilead’s hepatitis B virus treatment set for European approval

CHMP also recommends diabetes drugs from Sanofi and Novo Nordisk

- PMLiVE

Pharma ‘could do better’ on social media engagement

Industry is comfortable with the tech but has work to do on its approach

National Institute for Health and Care Excellence NICE logo

AstraZeneca’s Forxiga set to be recommended by NICE

The type 2 diabetes ‘triple therapy’ is backed in draft guidance

- PMLiVE

Yoshinori Ohsumi wins Nobel Prize in Medicine for autophagy work

Receives the accolade for his discoveries of mechanisms for the cell process

- PMLiVE

Novo Nordisk to cut 1,000 jobs as diabetes competition builds

Cites intensifying US market in particular for move to reduce costs

Sanofi reception

Sanofi trumpets new IGlarLixi data after regulatory delay

Reports that the combination drug is more effective at controlling glucose than Lantus alone

AstraZeneca AZ

AZ looks beyond diabetes with Forxiga trials

Will investigate dapagliflozin in kidney disease and heart failure

- PMLiVE

Jørgensen named Novo CEO-in-waiting as Sørensen plans retirement

Sørensen’s sooner-than-expected departure sparks executive team reshuffle

FDA approves Lilly-backed Bluetooth insulin device

Clears Companion Medical’s Bluetooth-enabled pen and smartphone app

Sanofi reception

Sanofi loses lead on diabetes combo IGlarLixi after FDA delay

FDA verdict on Novo Nordisk’s rival combo Xultophy due next month 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links